Is Kidney Damage From Lithium Reversible?

Kidney damage from lithium sits on a spectrum, and whether it reverses depends heavily on what kind of damage has occurred and how long it has been developing. Caught early, while changes are still mainly functional, much of the harm can slow or partially reverse after lithium is stopped. Once structural scarring sets in after years of treatment, the damage becomes largely permanent. The distinction between these two stages is the single most important thing to understand about lithium and the kidneys.

What Lithium Actually Does to the Kidneys

Lithium enters kidney cells through the same channel that sodium uses. Once inside the cells of the collecting duct, it disrupts the normal water-reabsorption machinery. The most immediate casualty is a protein called aquaporin-2 (AQP2), which acts as a water channel. Lithium treatment dramatically reduces AQP2 levels, which means the kidneys lose their ability to concentrate urine effectively.¹ This leads to a condition called nephrogenic diabetes insipidus (NDI), where you produce large volumes of dilute urine and feel constantly thirsty. Roughly 20% of patients on lithium develop NDI, though some estimates go as high as 40%.²

Over longer periods, lithium can cause structural changes in the kidney. Biopsies from long-term lithium patients show interstitial fibrosis (scarring between the tubules), sclerotic glomeruli (damaged filtering units), and cyst formation.³ There is also a surprisingly high rate of focal segmental glomerulosclerosis, a form of glomerular scarring found in half of biopsied cases in one study, which can lead to significant protein loss in the urine.⁴ This combination of tubular and glomerular injury is what makes chronic lithium nephropathy hard to fully undo.

Early Versus Late Damage

The timing question is central. Early in treatment, the kidney’s reduced ability to concentrate urine is probably a functional change rather than a structural one. The lithium is suppressing AQP2 production, but the underlying cells and architecture are still intact. At this stage, stopping lithium or lowering the dose can allow AQP2 levels to recover, and the concentrating defect may resolve.⁵

After years of lithium exposure, though, the story changes. The functional problem becomes embedded in structural damage: fibrosis replaces healthy tissue, filtering units scar over, and small cysts form. This is the point where reversibility drops off sharply. A subset of patients will still have a concentrating defect long after lithium is discontinued, because the cells responsible for concentrating urine have been permanently altered.² Animal studies confirm that even after lithium is stopped, the proteins involved in urine concentration recover unevenly and incompletely.⁶

So the honest answer is that early damage is often reversible, late damage usually is not, and there is a gray zone in between where partial recovery is possible but full recovery is unlikely.

What Happens to Kidney Function After Stopping Lithium

One of the clearest pieces of evidence on reversibility comes from a study that tracked kidney function before and after lithium was discontinued. Before stopping, patients were losing kidney function at an average rate of about 1.6 mL/min per year. After stopping, that decline essentially leveled off, falling to near zero. The difference was statistically clear and persisted over five years of follow-up. Patients who had the worst kidney function at the time they stopped lithium saw the largest benefit.⁷

This matters, but the nuance is important. For most patients, “improvement” meant their kidneys stopped getting worse, not that they bounced back to where they had been. A smaller number actually showed genuine recovery, with kidney function climbing back up. But the majority still experienced some continued decline, just at a much slower rate than before.⁷ A separate study looking specifically at patients who already had moderate kidney disease confirmed this pattern: after lithium withdrawal, most showed either an increase in kidney function or at least a reduced rate of decline.⁸

This is encouraging but falls short of what many patients hope for when they hear “reversible.” Stopping the accelerated damage is meaningful and can delay or prevent the need for dialysis. But if you are imagining your kidneys returning to their pre-lithium state after decades of use, that is unlikely for most people.

The Concentrating Defect That May Not Go Away

The most common kidney-related complaint during lithium treatment is excessive thirst and frequent urination, the hallmarks of NDI. For some patients, these symptoms resolve within weeks to months of stopping lithium. For others, the concentrating defect persists for years, sometimes indefinitely. Most patients who took lithium long-term still have a measurable impairment in urine-concentrating ability even after ending treatment.⁶

The reason for this persistence seems to relate to how lithium reshapes the cellular landscape of the collecting duct. It is not just that AQP2 levels drop; lithium also changes the ratio of different cell types in the kidney and causes structural remodeling that outlasts the drug itself.⁹ For patients whose NDI has been present for years, the practical expectation should be that some improvement in symptoms is likely after stopping lithium, but complete resolution is not guaranteed.

Acute Lithium Toxicity and the Kidneys

Most of the discussion about kidney damage from lithium centers on chronic, long-term use. But lithium can also cause acute kidney injury (AKI) when blood levels spike, whether from an intentional overdose, dehydration, a drug interaction, or a dosing error. A sudden rise in serum lithium can cause severe fluid loss through the kidneys, leading to a rapid drop in kidney function.¹⁰

Acute kidney injury from lithium toxicity is generally more reversible than chronic damage, provided it is caught and treated quickly. The kidneys recover once lithium levels come back down and hydration is restored. The danger is when acute episodes go unrecognized or when repeated acute toxicity layered on top of chronic use pushes already-stressed kidneys past a tipping point. Using the lowest effective lithium dose and closely monitoring blood levels are the most effective ways to prevent this from happening.¹⁰

How Common Is Severe Kidney Failure From Lithium

The fear that lithium will destroy your kidneys is understandable, given how often it comes up in patient forums. But end-stage renal disease (ESRD), meaning complete kidney failure requiring dialysis or transplant, is a rare outcome. Lithium does increase the risk compared to the general population, with one study estimating the relative risk at roughly eight times higher.¹¹ That sounds alarming in relative terms, but the absolute numbers paint a different picture.

In one long-term follow-up, about 1.5% of patients who started lithium in the 1960s and 1970s went on to develop ESRD. Among patients who started after 1980 (when monitoring practices improved), none had reached that point.¹² Reviews of the broader evidence agree that while a very small proportion of lithium-treated patients do face ESRD, most patients do not experience a clinically meaningful reduction in kidney function.¹³ The improvement in outcomes over the decades likely reflects better monitoring, lower target blood levels, and earlier detection of kidney changes.

The Glomerular Damage That Gets Overlooked

Most attention on lithium nephrotoxicity focuses on the tubules and the concentrating defect. But there is a lesser-known pattern of glomerular injury that deserves attention because it affects the prognosis differently. Focal segmental glomerulosclerosis (FSGS), a type of scarring in the kidney’s filtering units, has been found at a surprisingly high rate in lithium patients who undergo biopsy. One study found FSGS in half of biopsied cases, with significant protein spillage into the urine in those with more severe scarring.⁴

This matters because FSGS is generally not reversible. It represents permanent structural loss, and its presence alongside the more familiar tubular damage suggests that lithium nephrotoxicity is a broader assault on the kidney than often appreciated. Patients with heavy protein loss in their urine while on lithium should be evaluated carefully, as this may indicate glomerular involvement that carries a worse prognosis for recovery.¹⁴

Can Amiloride Protect the Kidneys During Lithium Treatment

One of the more interesting developments in managing lithium’s kidney effects involves amiloride, a mild diuretic. Research has shown that lithium enters kidney cells through the epithelial sodium channel (ENaC), the same channel amiloride blocks. By blocking this channel, amiloride reduces the amount of lithium that gets into kidney cells in the first place, which in turn prevents the suppression of AQP2 and the cascade of changes that lead to NDI. In animal studies, amiloride given alongside lithium prevented the drop in AQP2, preserved the normal cell-type ratio, and reduced excessive urine output.⁹

This is not a cure for established damage, but rather a prevention strategy. The rationale is compelling: if you can keep lithium out of the kidney cells that it harms, you may be able to get the psychiatric benefits of lithium while reducing the renal cost. Some clinicians already prescribe amiloride alongside lithium for patients who develop polyuria, though its use is not yet standardized in treatment guidelines. It’s worth discussing with your prescriber if you’re on lithium and noticing increased thirst or urine volume.

Drugs That Make Lithium’s Kidney Effects Worse

Lithium’s kidney safety is not determined by lithium alone. Several commonly prescribed drugs can raise lithium levels in the blood by reducing its clearance through the kidneys, pushing patients into toxic territory without any change in their lithium dose. The major offenders include ACE inhibitors and angiotensin receptor blockers (both widely used for blood pressure), non-steroidal anti-inflammatory drugs like ibuprofen and naproxen, and certain diuretics.¹⁵

The practical risk here is that a patient might be stable on lithium for years, develop high blood pressure, get prescribed an ACE inhibitor, and then slide into lithium toxicity within weeks because nobody adjusted the lithium dose. Similarly, reaching for over-the-counter ibuprofen during a headache or menstrual cramps can spike lithium levels in a way that most patients would not expect. If you’re on lithium, this is one of those cases where your pharmacist may be as important as your psychiatrist in catching dangerous combinations.

The Psychiatric Trade-Off of Stopping Lithium

Any discussion of stopping lithium to protect the kidneys has to reckon with what happens to the condition lithium was treating in the first place. Lithium remains one of the most effective mood stabilizers for bipolar disorder, with uniquely strong evidence for reducing suicide risk. Stopping it is not a neutral act. Sudden withdrawal of lithium significantly raises the risk of relapse, with more than half of patients experiencing a recurrence within ten weeks of stopping.¹⁶

A decision analysis looking at this trade-off found that even twenty years into treatment, lithium still came out as the preferred option for most patients. Switching to alternatives would only make sense if the risk of progressing to complete kidney failure exceeded about 40%, or if alternative medications worked equally well at preventing relapse, which for most patients they do not.¹⁷ This is the uncomfortable reality: for many people, the risk of untreated or poorly treated bipolar disorder, including suicide, outweighs the small absolute risk of severe kidney damage. The decision to continue or stop lithium should involve both a psychiatrist and a nephrologist, and if discontinuation is chosen, it should be done gradually to minimize rebound mania or depression.

Early Detection Through Newer Biomarkers

Standard kidney monitoring during lithium treatment relies on blood creatinine levels and estimated filtration rate (eGFR), but these measures are insensitive to early tubular damage. By the time eGFR drops noticeably, significant injury has already accumulated. Researchers have investigated whether newer biomarkers could catch lithium-related kidney damage sooner. One study found that lithium-treated patients had elevated levels of plasma NGAL and urinary beta-2 microglobulin (β2-MG) compared to bipolar patients not taking lithium, even when their standard kidney tests were still in the normal range. In men, urinary β2-MG correlated with both the duration of lithium treatment and conventional markers of kidney function, suggesting it could serve as an early warning signal of tubular stress.¹⁸

These biomarkers are not yet part of routine clinical monitoring for lithium patients, but they point toward a future where kidney damage could be detected and addressed before it reaches the irreversible stage. For now, the best approach remains regular monitoring of blood levels, kidney function tests, and urine concentration, with the understanding that these tools catch damage later than we would like. If your doctor checks only lithium levels without periodically measuring kidney function and urine-concentrating ability, you should ask why.

Why the Answer Differs So Much Between Patients

One reason patients get confused by the information available on lithium and kidneys is that the outcomes vary enormously from person to person. Some people take lithium for thirty years with no measurable kidney impact. Others develop significant kidney disease within a decade. The factors that seem to matter include the duration of treatment, the average lithium blood level maintained over time, how many episodes of toxicity have occurred, age, pre-existing kidney function, and concurrent medications. Patients who had their lithium levels run higher in earlier decades, before modern monitoring recommendations, appear to have fared worse than those managed with today’s lower target ranges.¹²

This variability also means that blanket statements about reversibility are always going to be incomplete. A patient who stops lithium after five years with only mild concentrating issues has a fundamentally different prognosis from one who stops after twenty-five years with fibrosis and reduced filtration rate. The most useful way to think about it is not as a binary question but as a sliding scale: the earlier you catch the problem and act, the more of the damage can be slowed or reversed. The later you intervene, the more you are managing a permanent condition rather than reversing one.

1
PubMed Central. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation
2
The Journal of the American Board of Family Practice. Lithium-Induced Nephrogenic Diabetes Insipidus
3
PubMed Central. MRI findings in chronic lithium nephropathy: a case report
4
Journal of the American Society of Nephrology. Lithium Nephrotoxicity: A Progressive Combined Glomerular and Tubulointerstitial Nephropathy
5
PubMed. Lithium and the kidney: an updated review
6
PubMed Central. Expression of transporters involved in urine concentration recovers differently after cessation of lithium treatment
7
PubMed Central. Kidney function decline improves after lithium discontinuation
8
PubMed. Renal function after withdrawal of lithium
9
PubMed. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus
10
PubMed. Diagnosis and Management of Acute and Chronic Lithium-Associated Nephrotoxicity
11
PubMed. End-stage renal disease associated with prophylactic lithium treatment
12
PubMed. Effects of 10 to 30 years of lithium treatment on kidney function
13
PubMed Central. Key questions on the long term renal effects of lithium: a review of pertinent data
14
PubMed. Focal segmental glomerulosclerosis in patients receiving lithium carbonate
15
PubMed Central. Lithium therapy and its interactions
16
PubMed Central. Lithium withdrawal and relapse in bipolar disorder when kidney function deteriorates
17
PubMed Central. A decision analysis of long-term lithium treatment and the risk of renal failure
18
PubMed Central. Novel markers of kidney injury in bipolar patients on long-term lithium treatment